Article thumbnail

During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein

By Marcela D Salazar, Maya Ratnam, Mugdha Patki, Ivana Kisovic, Robert Trumbly, Mohamed Iman and Manohar Ratnam
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). AD: Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
  2. (2004). All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor beta to stimulate apoptosis in MCF-7 breast cancer cells.
  3. (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood)
  4. (2002). Aromatase inhibitors in breast cancer. Trends Endocrinol Metab
  5. (1993). Chambon P: Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region.
  6. (1991). Chambon P: Multiple isoforms of the mouse retinoic acid receptor alpha are generated by alternative splicing and differential induction by retinoic acid.
  7. (2009). Coates AS: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
  8. (2002). Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer
  9. (2010). Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev
  10. (2003). Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
  11. (2006). DC: Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell
  12. (2009). De Bortoli M: ERalpha as ligand-independent activator of CDH1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci USA
  13. (2006). Decensi A: Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer
  14. (2008). Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res
  15. (1999). EA: Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.
  16. (2006). Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr Relat Cancer
  17. (2004). Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res
  18. (2008). ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
  19. (2006). Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures.
  20. (2007). Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen. Oncogene
  21. (1998). Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol
  22. (2007). Fenretinide and risk reduction of second breast cancer. Nat Clin Pract Oncol
  23. (2001). Ford LG: From adjuvant therapy to breast cancer prevention:
  24. (2006). GK: affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics
  25. (2001). Gronemeyer H: The promise of retinoids to fight against cancer. Nat Rev Cancer
  26. (1996). Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity.
  27. (1997). Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene
  28. (2006). Ioannidis JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
  29. (2007). JF: Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res
  30. (2009). KP: Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell
  31. (2003). Lynch KP: Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer
  32. (2009). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
  33. (2008). Minireview: nuclear receptors and breast cancer. Mol Endocrinol
  34. (2004). MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: status report
  35. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet
  36. (2003). Pazdur R: Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res
  37. (1998). Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res
  38. (2004). RI: Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
  39. (2009). RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer
  40. (1999). Role of retinoid receptors in the prevention and treatment of breast cancer.
  41. (2008). S: Genomewide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res
  42. (2009). Shioda T: Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA
  43. (2009). Stunnenberg HG: Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer
  44. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc
  45. (2007). Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem
  46. (2005). Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet
  47. (2003). U: A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
  48. (2002). VC: Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
  49. (2002). YLR: Retinoic acid receptor alpha2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. Cell Growth Differ